http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1412390-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd1fcf383108255c0c37f8a99d0df33f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2002-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27b0765e09fe1d0662bc7666ad20388a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85e8d3c537195f8979793af5118f13c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f3c63429400901e9461858b3e0bbbe0 |
| publicationDate | 2004-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1412390-A2 |
| titleOfInvention | Agents that activate or inhibit toll-like receptor 9 |
| abstract | The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255Cys-Arg-Arg 258Cys (as CRRC) or at 265Cys-Met-GIu 268Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen. |
| priorityDate | 2001-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 210.